Navigation Links
FDA Statement on Makena

SILVER SPRING, Md., Nov. 8, 2011 /PRNewswire-USNewswire/ -- FDA approved Makena (hydroxyprogesterone caproate) in February 2011 for the reduction of the risk of certain preterm births in women who have had at least one prior preterm birth.  For many years before Makena was approved, a version of the active ingredient of Makena has been available to patients whose physicians requested the drug from a pharmacist who compounded the drug.  In March 2011, after learning that the owner of Makena, K-V Pharmaceuticals, had sent letters to pharmacists indicating that FDA will no longer exercise enforcement discretion with regard to compounded versions of Makena, FDA issued a statement about compounded hydroxyprogesterone caproate to clarify the agency's enforcement priorities.  In the March 2011 statement, FDA explained that the agency prioritizes enforcement actions related to compounded drugs using a risk-based approach, giving the highest enforcement priority to pharmacies that compound products that are causing harm or that amount to health fraud.  The agency also stated:


In order to support access to this important drug, at this time and under this unique situation, FDA does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate based on a valid prescription for an individually identified patient unless the compounded products are unsafe, of substandard quality, or are not being compounded in accordance with appropriate standards for compounding sterile products. As always, FDA may at any time revisit a decision to exercise enforcement discretion.

In October 2011, FDA received information from K-V Pharmaceuticals regarding the potency and purity of samples of bulk hydroxyprogesterone caproate active pharmaceutical ingredients (APIs) and compounded hydroxyprogesterone caproate products.  According to the analysis of this information provided by K-V, there is variability in the purity and potency of both the bulk APIs and compounded hydroxyprogesterone caproate products that were tested.  Although FDA has not validated or otherwise confirmed the analyses provided by K-V, FDA has carefully reviewed the data and will conduct an on-site review of the laboratory analyses.

FDA has begun its own sampling and analysis of compounded hydroxyprogesterone caproate products and the bulk APIs used to make them.  That process is ongoing.  In the meantime, we remind physicians and patients that before approving the Makena new drug application, FDA reviewed manufacturing information, such as the source of the API used by its manufacturer, proposed manufacturing processes, and the firm's adherence to current good manufacturing practice.   Therefore, as with other approved drugs, greater assurance of safety and effectiveness is generally provided by the approved product than by a compounded product.

Media Inquiries: Shelly Burgess, 301-796-4651,

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering
2. Alere Inc. Statement Regarding Recommended Increased Cash Offer to Acquire Axis-Shield
3. Alere Inc. Statement Regarding Axis-Shield Offer
4. Alere Inc. Statement Amending Acceptance Condition to Axis-Shield Offer
5. Visual Healthcare Corp. Files Year-End Disclosure Statement
6. Statement from the Michigan Society of Anesthesiologists in Response to Governor Snyders Health & Wellness Announcement
7. Vycor Medical, Inc. Files Restated Financial Statements
8. Vycor Medical, Inc. Restatement of Financial Statements
9. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
10. Statement on Availability of Primatene® Mist CFC
11. Jonah and Dina Shacknai Issue Statement Regarding the Release of Paradise Valley Police Reports
Post Your Comments:
(Date:11/24/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ("Ascendant" ... has declared a special 1 percent stock dividend on the ... 14, 2015, to shareholders of record December 7, 2015.  The ... of common stock. --> ... endorsement of our confidence in Ascendant,s growth strategy as well ...
(Date:11/24/2015)... 24, 2015  Figure 1, a free mobile-first network ... cases, has launched a new completely redesigned web version ... allows radiologists, who work primarily on a desktop, to ... with its radiologist user base, Figure 1 is hosting ... North America (RSNA) Annual Meeting. ...
(Date:11/24/2015)... Nov. 24, 2015  Family Rentals, a ... the launch of their newly designed, mobile-responsive website. ... --> Logo - ... --> Now, renting essential items ... vacation, just got a whole lot easier through ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 2015 , ... Young patients with a wide variety of dental needs can ... S. Lele, who are pediatric dentists in Tucson, AZ . Unlike traditional treatment ... system causes minimal discomfort and bleeding to the patient during treatment and the following ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November ... determine which patients are or are not eligible for bariatric surgery. The article explains ... 40, are more than 100 pounds overweight, or have a BMI of 35 and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The hospitals ... to several aspects of orthopedic care. They have received recognition for excellence from ... orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based on ...
(Date:11/24/2015)... ... 24, 2015 , ... The Trustees, Massachusetts’ largest conservation and ... fees at several of their most popular properties, including Crane Beach in Ipswich, ... REI’s Black Friday #OptOutside Campaign. The Trustees encourage families and friends to take ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), the ... Company as its newest Partner Firm. Based in Jefferson City, Missouri, their core ... advisor regardless of whether that client is a business, a family, or an ...
Breaking Medicine News(10 mins):